T082: AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients

• Ninja Övergaard,
• Kjersti Lia,
• Peter Asdahl,
• Per Wikman,
• Ingrid Glimelius,
• Ingemar Lagerlöf.,
• Ann-Sofie Johansson,
• Lotta Hansson,
• Gunilla Enblad,
• Johan Linderoth,
• Christina Goldkuhl,
• Alexander Fosså,
• Peter Kamper,
• Daniel Molin

Affiliations

Ninja Övergaard

1 Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Kjersti Lia

2 Department of Oncology, Oslo University Hospital

Peter Asdahl

4 Department of Hematology, Aarhus University Hospital, Denmark

Per Wikman

1 Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Ingrid Glimelius

1 Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Ingemar Lagerlöf.

5 Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

Ann-Sofie Johansson

7 Department of Oncology, Umeå University, Sweden.

Lotta Hansson

8 Haematology unit, Karolinska University Hospital, Stockholm, Sweden.

Gunilla Enblad

1 Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Johan Linderoth

9 Department of Oncology, Lund University, Lund, Sweden.

Christina Goldkuhl

10 Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Alexander Fosså

11 Department of Oncology, Oslo University Hospital, Norway.

Peter Kamper

4 Department of Hematology, Aarhus University Hospital, Denmark

Daniel Molin

1 Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.